A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region
Latest Information Update: 23 Aug 2024
Price :
$35 *
At a glance
- Drugs MRNA 1325 (Primary)
- Indications Zika virus infection
- Focus Adverse reactions; First in man
- Sponsors Moderna Therapeutics; Valera LLC
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.
- 24 Apr 2019 Planned End Date changed from 1 Apr 2019 to 1 May 2019.
- 24 Apr 2019 Planned primary completion date changed from 1 Apr 2019 to 1 May 2019.